44 results about "Deoxyschizandrin" patented technology

The invention relates to a Chinese magnoliavine fruit monomer composition separation preparation method; ethanol extracts from Chinese magnoliavine fruit are extracted by petroleum ether, chromatography is carried out to the petroleum ether extracts by a silicagel column, and then the petroleum ether is eluted by petroleum ether-ethylacetate, and HPLC is used for monitoring, and then crude extract A and crude extract B are fraction-collected, and eluted; the volume ratio of eluant petroleum ether and ethylacetate is 3-5:1, the crude extract A and crude extract B are respectively applied to a high-speed counter-current chromatography for separation, so as to obtain SCHisanhenol, deoxyschizandrin, schizandrin B, schisandrin C, schizandrol A, schizandrol B and schisantherrin B monomers, and the purity is higher than 98 percent.

The invention discloses a method for extracting, separating and preparing lignin monomers from schisandra chinensis. The method comprises the following steps: performing supercritical extraction on schisandra chinensis medicinal powder by using CO2 to obtain a crude extract; performing primary high-speed counter-current chromatographic separation on the crude extract; forming a solvent system A by using hexane, ethyl acetate, methyl alcohol and water in the volume ratio of (2-10):(0-10):(0-10):5, wherein the upper phase A is a stationary phase A and the lower phase A is a mobile phase A; preparing a first schizandrol, a second schizandrol and a third schizandrol; recovering the separated stationary A to serve as a sample to be tested; performing secondary high-speed counter-current chromatographic separation; forming a solvent system B by using hexane, ethyl acetate, methyl alcohol and water in the volume ratio of (1-10):(0-4):(0-9):1, wherein the upper phase B is a stationary phase B, and the lower phase B is a mobile phase B; preparing deoxyschizandrin and schisandrin b. By adopting the method which integrates supercritical extraction and high-speed counter-current chromatographic separation, the deoxyschizandrin and the schisandrin b can be directly used for separating and purifying subsequent monomers without complex sample treatment after the extraction; the steps of extracting and separating are simple and efficient.

A composition including an aliquot of the herb Herba Epimedii; and an aliquot of at least three supplemental herbs selected from the group consisting of Fructus Rosae Laevigatae; Fructus Rubi; Fructus Psoralea; Radix Morindae Officinalis; Fructus Schisandrac Chinensis; Fructus Ligustri Lucidi; Semen Cuscutae; and Radix Astragali. A composition including icariin; ursolic acid; ellagic acid; psoralen; deoxyschizandrin; oleanolic acid; quercetin; aslvagaloside; and an extract of the herb Radix Morindae Officinalis. Methods including administering a composition directed at treatment of various kidney disorders or the promotion of kidney health and to the overall health of the kidney, including the use of a composition in the treatment of prostate cancer, prophylatic prostate health, reduction of polyuria, incontinence, proteinuria, as well as for sexual satisfaction.

The invention discloses a traditional Chinese medicine preparation lumbus-strengthening kidney-tonifying pill detection method, according to the method, rehmannia glutinosa, yam, tuckahoe, schisandra, chrysanthemum and astragalus in a lumbus-strengthening kidney-tonifying pill can be microscopically identified, a radix angelicae sinensis referenee crude herb, ginsenoside Rg1, ginsenoside Re, ginsenoside Rb1, dipsacus asper saponin VI, astragaloside and deoxyschizandrin are used as reference substances, whether the lumbus-strengthening kidney-tonifying pill contains the radix angelicae sinensis ,ginseng, dipsacus asper, astragalus and schisandra can be identified by thin-layer chromatography; the dipsacus asper saponin VI content in the lumbus-strengthening kidney-tonifying pill preparation can be detected by HPLC, according to the detection method, the quantitative index is that the dipsacus asper saponin VI (C47H76O18) content in every 1g of the traditional Chinese medicine preparation lumbus-strengthening kidney-tonifying pill may not be less than 0.60mg, the controllability of quality standards of the traditional Chinese medicine preparation lumbus-strengthening kidney-tonifying pill can be improved to further ensure the product intrinsic quality and effect, so that the quality standard is more perfect, and the drug quality control level is improved.

The invention provides a method for measuring the content of a Shenqi blood sugar reducing preparation. The method is used for measuring the content of 10 active ingredients in the Shenqi blood sugar reducing preparation: ginsenoside Rb1, ginsenoside Rc, ginsenoside Rd, ginsenoside Rg1, ginsenoside Re, astragaloside, deoxyschizandrin, schisandrol A, schisandrol B. In the invention, with the guidance of blood sugar reducing activity of a compound, multiple active substances in the compound are detected, and the quality level of the whole compound preparation can be reflected better; meanwhile, a Q-MS ion monitoring mode is selected for content measurement, and the mass spectrum quantification has high accuracy, specificity and sensitivity and is superior to traditional HPLC analysis method; and moreover, fingerprint is established according to the liquid phase diagrams of different batches of Shenqi blood sugar reducing preparations obtained by the method, the similarity is evaluated, the inherent quality of the Shenqi blood sugar reducing preparation product is evaluated more scientifically and comprehensively, and a basis is provided for establishing a quality standard of higher level.

This invention relates to a method of preparing high-purity Schisandrin B. The invention adopts analysis mode high speed counter-current chromatography to proceed small scale preparation, adopt semipreparative type high speed counter-current chromatography to proceed large-scale preparation. The feature is that in solvent system the volume ratio of normal hexane, methanol, water and acetonitrile is 5 - 11 : 3 - 6 : 2 - 5 : 1, and the best volume ratio is 10:5:4:3. The invention does not need solid padding, has no irreversible adsorption and no pollution.The purity of gained Schisandrin B can reach 98%upwards.

The invention relates to a method for detecting dissolving rate of oral administration solid preparation which is prepared by using schisandra fruit extract as the active constituent, wherein ethanol solution, or thin hydrochloric acid or water is used as the dissolving out medium, and high performance liquid phase chromatographic method is employed to detect the dissolving quantity of Deoxyschizandrin in the oral administration solid preparation of schizandrol extract.

The invention discloses an application of deoxyschizandrin in preparation of drug for treating cholestasis liver injury. Deoxyschizandrin has molecular formula of C24H32O6 and molecular weight of 416.51, and has the structural formula shown in the description. Mouse liver injury induced by application of excessive lithocholic acid (LCA) is taken as a model. After application of deoxyschizandrin, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in serum are significantly lowered, while necrosis degree of liver cells is significantly improved. The results indicate that deoxyschizandrin has treatment effect for liver injury induced by LCA, and can be used for treating cholestasis liver injury clinically.

The invention relates to an endophytic fungi for improving content of main active ingredients of schisandra chinensis through a fermentation method. The endophytic fungi is Aspergilluspenicillioides WT4 which is preserved in the China Center for Type Culture Collection (CCTCC) with preservation numbers of CCTCC No: M2012043 in Wuhan University in Wuhan city, and the preservation date is February 29, 2012. The WT4 in the endophytic fungi can remarkably improve the main active ingredients of the schisandra chinensis, such as schizandrin, schisantherin, deoxyschizandrin and schisandrin b. Therefore, in the raw material production with the purpose of obtaining the schizandrin, the schisantherin, the deoxyschizandrin and the schisandrin b, people can select schisandra chinensis endophytic fungi WT4 to ferment the schisandra chinensis to improve the yield and save medicinal resources.

The invention relates to a method for evaluating quality of FRUCTUSSCHISANDRAE SPHENANTHERAE in commercially available Chinese patent medicines by using a flash-gas chromatography. The method comprises the steps of putting a powdered or liquid Chinese patent medicine sample, which contains the FRUCTUSSCHISANDRAE SPHENANTHERAE, into a pyrolyzer, and placing the pyrolyzer at a sample inlet of a gas chromatograph; when the temperature of the pyrolyzer reaches a certain value, carrying out sample introduction; detecting the sample by using the gas chromatograph to obtain a gas chromatogram; carrying out qualitative analysis on a lignan component in the Chinese patent medicine sample by using standard material retention time, and determining the corresponding peak positions of anwuligan, deoxyschizandrin and schisantherin in the gas chromatogram; (2) then, using the flash-gas chromatography to carry out quantitative analysis on the deoxyschizandrin and the schisantherin in the Chinese patent medicine sample by means of an external standard method; if the quantitative result shows that the relative contents of the deoxyschizandrin and the schisantherin in the Chinese patent medicine sample are within a range of 1.50-2.0, proving that the quality of the FRUCTUSSCHISANDRAE SPHENANTHERAE in the Chinese patent medicine sample is better, and otherwise, proving that the quality of the fructus schisandrae in the Chinese patent medicine sample is poorer. The method has the characteristics of being simple, environmentally friendly and efficient.

The invention discloses a method for carrying out simultaneous determination on contents of schisandrin, schisantherin, deoxyschizandrin and schisandrin B in a Chinese magnoliavine raw material or a Chinese magnoliavine extract. The method employs means of crushing, sieving, methanol ultrasonic extraction, calibrating volume and filtering to treat schisandra chinensis or a Chinese magnoliavine extract to obtain a sample solution for testing; a high performance liquid chromatography is utilized for simultaneous determination on contents of four lignan components. The method utilizes a reverse direction distribution chromatographic theory to carry out analysis on the sample by gradient elution, under conditions of a column temperature of 25-45 DEG C, mobile phases of methanol and 0.05-0.2% trifluoroacetic acid aqueous solution (methanol and trifluoroacetic acid aqueous solution in a volume ratio of 50:50-100:0), an elution time of 30-60 min, a flow velocity of 0.7-1.5 ml / min and a detection wavelength of 210-280 nm. The quality detection method is simple, rapid, sensitive and accurate.

The invention discloses an application of a schisandra chinensis monomer compound in preparation of drugs for prevention and treatment of hepatotoxicity caused by acetaminophen (APAP), wherein the schisandra chinensis monomer compound is deoxyschizandrin, schisandrin C, schisandrin or schisantherin a. Experiment results show that: with the schisandra chinensis monomer compound, the ALT content and the AST content in the APAP-induced liver injury animal model can be significantly reduced, consumption of glutathione in liver cells can be inhibited, the liver cell necrosis degree can be effectively improved, and the schisandra chinensis monomer compound provides significant treatment and protection effects for hepatotoxicity symptoms caused by APAP.

The invention discloses a Chinese magnoliavine active extract, which comprises schisandrin, deoxyschizandrin, and schisandrin B. The preparation method comprises reflux extraction, concentration and water precipitation, adsorption, elution, and drying. Ethanol (85-95%) is used to extract the Chinese magnoliavine active substances through reflux extraction; then the active substances are purified by water precipitation, adsorption, macroporous resin elution, and reversed-phase high-performance liquid chromatography to obtain schisandrin, deoxyschizandrin, and schisandrin B, and the product quality is high. The production technology is simple, each operation has accurate data, the repeatability is good, the product quality is stable, ethanol is low in toxicity, and the extracted Chinese magnoliavine active substances are very safe and green.

The invention relates to an application of deoxyschizandrin in preparation of cosmetics or externally-applied medicines with functions of resisting light aging or removing acnes and diminishing inflammation. The mass content of Chinese magnoliavine fruit lignan in deoxyschizandrin is not less than 5%, and the use amount of deoxyschizandrin in the cosmetics or the externally-applied medicines is 0.01-10% in percentage by mass. The application disclosed by the invention has the advantages that researches show that deoxyschizandrin has relatively good anti-light-aging effects, also has a relatively good anti-inflammatory effect on inflammation caused by propionibacterium acne, and can be used for preparing the cosmetics or the externally-applied medicines with the effects of resisting light aging or removing the acnes and diminishing inflammation.

This invention relates to a preparation method of high-purity deoxyschizandrin. The process as follows: the solvent system includes normal hexane, methanol and water; the volume ratio of normal hexane, methanol and water is 2 - 6: 3 - 7: 4 - 8; firstly dissolve deoxyschizandrin crude extract perpared by traditional craft in 2ml - 10ml bottom phase; adopt analysis mode high speed counter-current chromatography to proceed small scale preparation, adopt semipreparative type high speed counter-current chromatography to proceed large-scale preparation. The invention does not need solid padding, has no irreversible adsorption and no pollution. The purity of gained deoxyschizandrin can reach 94%upwards.

The invention discloses a preparation for auxiliary protection against chemical liver injury. The preparation is mainly prepared by deoxyschizandrin and procyanidine, and has a precise curative effect on liver injuries of various types.

The invention relates to a traditional Chinese medicine monomer, i.e. deoxyschizandrin. The traditional Chinese medicine monomer can inhibit the ADP-induced platelet aggregation promotion effect. Theinvention further discloses the fundamental research of deoxyschizandrin as a novel anti-platelet aggregation drug in thrombosis.

The invention discloses application of deoxyschizandrin to preparation of a medicine for treating diabetes and provides a pharmaceutical composition taking the deoxyschizandrin as an active ingredient. The pharmaceutical composition is capable of decreasing blood sugar remarkably and is far higher than first-line medicine metformin in the market in acting sensitivity.

The invention discloses an application of a Schisandra sphenanthera Rehd.et Wils. extract in preparation of a medicament for treating a liver injury caused by acetaminophen (APAP). The main ingredients of the Schisandra sphenanthera Rehd.et Wils extract are schisantherin and deoxyschizandrin. Experiments find that the Schisandra sphenanthera Rehd.et Wils. extract can significantly resist serum ALT (alanine aminotransferase)and AST (aspartate amino transferase)level rise and necrosis of liver cells caused by the liver injury caused by APAP, and inhibits consumption of reductive glutathione in the liver cells, so as to relieve the liver injury degree caused by the APAP. The mechanism relates to activation of an Nrf2-ARE (NF-E2-related factor 2-antioxidative responsive element) signal channel, is manifested by raising mRNA (messenger Ribonucleic Acid) expression of Nrf2, facilitating Nrf2 nuclear translocation, starting a downstream medicament-metabolizing enzyme and transcribing an antioxidant gene. The experiment result shows that the Schisandra sphenanthera Rehd.et Wils. extract has a treatment effect on the liver injury caused by the APAP, and novel method and means are provided for clinical prevention and treatment of the liver injury caused by the APAP.